2 June 2025 – TheNewswire - (Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today announced that the Company has appointed Rohit Babbar, CPA as Chief Financial Officer (“CFO”) of the Company, replacing James B. Murphy, CPA as Fractional CFO.

 

Rohit Babbar is Certified Public Accountant with fourteen years of experience leading accounting operations and financial strategy across fast-growing private and publicly listed small to mid-sized companies in Canada and the US. He is a Director at Brio Financial Group (“Brio”), a financial consulting firm that provides outsourced CFO services, financial planning and analysis, and strategic advisory support to emerging growth companies. Over the course of his career, Mr. Babbar has delivered impact across strategic growth and operational efficiency, leading transformative initiatives such as a USD 50 million private equity deal that helped drive a tenfold revenue increase from USD 20 million to USD 200 million. Mr. Babar will be supported by an experienced team of professionals from Brio specializing in accounting and finance, capital raising and administrative operations, as Helix enters a new phase of growth that includes plans to relocate to the US, pursue a NASDAQ listing, and close a substantial equity financing to support upcoming clinical studies.

 

“Rohit’s leadership and Brio’s support will provide the bandwidth we need as we prepare to execute on the Company’s upcoming strategic milestones—particularly as we gear up for our interactions with the FDA—ensuring our financial operations are aligned and fully resourced to support clinical execution,” said Dr. Thomas Mehrling, MD, PhD, CEO of Helix BioPharma.

 

Rohit Babbar, CPA, CFO of Helix added: “I’m excited to join Helix at such a pivotal stage in its evolution. The Company’s scientific foundation and strategic direction present a compelling opportunity to build long-term value. I look forward to working closely with the team to help drive its financial strategy and support its upcoming milestones.”

 

About Brio Financial Group

Brio Financial Group is a financial and management consulting firm based in Somerville, New Jersey, specializing in outsourced financial leadership and reporting support for small to mid-sized public and private companies. With a team experienced across domestic and international markets, Brio has supported clients listed on multiple stock exchanges and is frequently referred by leading audit firms—including sole practitioners and Big Four firms alike. Brio’s services span complex financial analysis, accounting for mergers and acquisitions, valuation of financial instruments, and the development of robust financial reporting frameworks. In addition to ensuring compliance and managing financial reporting and taxation, the firm provides strategic financial management solutions, including budgeting, modeling, capital procurement, and accounting system design. Brio is known for helping emerging growth companies navigate financial complexity with clarity and confidence.

 

About Helix BioPharma Corp.

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

 

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, please visit: https://www.helixbiopharma.com/

 

For more information, please contact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2

Toronto, ON M5H 0B4

Tel: +1 857 208 7687

Jacek Antas, Director

corporate@helixbiopharma.com

  

Forward-Looking Statements and Risks and Uncertainties

This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to DOS47, LR 09 and GEMCEDA. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

 

Forward-looking statements are necessarily based on a number of estimates and assumptions that the Company considered appropriate and reasonable as of the date such information is given, including but not limited to the assumptions regarding the implied benefits of the transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the risk that the Company's assumptions on which its forward-looking statements are based may not be accurate; the ability of the Company to capitalize on the potential benefits of the transactions; and the risk factors disclosed in the Company's periodic reports publicly filed and available on its SEDAR+ profile at www.sedarplus.ca. No assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur. There is no assurance that the proposed transactions will be completed in accordance with its terms or at all. The forward-looking statements contained in this news release are made as of the date of this announcement and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.